<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04660812</url>
  </required_header>
  <id_info>
    <org_study_id>ARC-9</org_study_id>
    <nct_id>NCT04660812</nct_id>
  </id_info>
  <brief_title>An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer.</brief_title>
  <official_title>A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcus Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase 1b/2 open-label study will evaluate the efficacy of etrumadenant&#xD;
      (AB928) treatment combinations in patients with metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label Phase 1b/2 study in participants with metastatic colorectal&#xD;
      cancer that will assess the efficacy of etrumadenant.&#xD;
&#xD;
      Approximately 250 participants will be enrolled to 1 of 3 cohorts:&#xD;
&#xD;
      Cohort A) etrumadenant + zimberelimab +mFOLFOX-6 +/-bev vs mFOLFOX-6 +/-Bev&#xD;
&#xD;
      Cohort B) etrumadenant + zimberelimab +mFOLFOX-6 +/-bev vs regorafenib&#xD;
&#xD;
      Cohort C) chemotherapy-free combinations of etrumadenant + zimberelimab + other agents&#xD;
&#xD;
      The primary objective of this clinical study is to evaluate the safety of etrumadenant-based&#xD;
      combination therapy in participants with metastatic colorectal cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">December 18, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From randomization until death from any cause (up to approximately 3-7 years)</time_frame>
    <description>PFS as assessed by RECIST v1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From randomization until death from any cause (up to approximately 3-7 years)</time_frame>
    <description>ORR according to RECIST v1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From randomization until death from any cause (up to approximately 3-7 years)</time_frame>
    <description>ORR according to RECIST v1.1</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">247</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>etrumadenant + zimberelimab + mFOLFOX-6 +/- bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive oral etrumadenant in combination with zimberelimab +mFOLFOX-6 +/-bevacizumab by IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mFOLFOX-6 +/-bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive mFOLFOX-6 +/- bevacizumab by IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>regorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive oral regorafenib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>etrumadent+ zimberelimab + AB680</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive oral etrmadenant in combination with zimberelimab +AB680 by IV infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etrumadenant</intervention_name>
    <description>Dual adenosine receptor (A2aR and A2bR) antagonist</description>
    <arm_group_label>etrumadenant + zimberelimab + mFOLFOX-6 +/- bevacizumab</arm_group_label>
    <arm_group_label>etrumadent+ zimberelimab + AB680</arm_group_label>
    <other_name>AB928</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zimberelimab</intervention_name>
    <description>Zimberelimab is a fully human anti-PD-1 monoclononal antibody</description>
    <arm_group_label>etrumadenant + zimberelimab + mFOLFOX-6 +/- bevacizumab</arm_group_label>
    <arm_group_label>etrumadent+ zimberelimab + AB680</arm_group_label>
    <other_name>AB122</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOX-6 regimen</intervention_name>
    <description>mFOLFOX-6 regimen is administered as part of standard chemotherapy regimen</description>
    <arm_group_label>etrumadenant + zimberelimab + mFOLFOX-6 +/- bevacizumab</arm_group_label>
    <arm_group_label>mFOLFOX-6 +/-bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Bevacizumab is administered as part of standard chemotherapy regimen</description>
    <arm_group_label>etrumadenant + zimberelimab + mFOLFOX-6 +/- bevacizumab</arm_group_label>
    <arm_group_label>mFOLFOX-6 +/-bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>regorafenib</intervention_name>
    <description>Regorafenib is adminstered as part of standard chemotherapy regimen</description>
    <arm_group_label>regorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB680</intervention_name>
    <description>AB680 is a cluster of differentiated CD73 Inhibitor</description>
    <arm_group_label>etrumadent+ zimberelimab + AB680</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female participants â‰¥ 18 years of age&#xD;
&#xD;
          -  Histologically confirmed metastatic colorectal adenocarcinoma&#xD;
&#xD;
          -  Must have at least 1 measurable lesion per RECIST v1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Life expectancy at least 3 months&#xD;
&#xD;
          -  Adequate hematologic and end-organ function&#xD;
&#xD;
          -  Negative HIV, Hep B and Hep C antibody testing&#xD;
&#xD;
          -  Agreement to remain abstinent or use contraceptive measures with female partners of&#xD;
             reproductive potential, and agreement to refrain from donating sperm, for 30 days&#xD;
             after the last dose of etrumadenant, 90 days after the last dose of zim, 180 days&#xD;
             after mFOLFOX-6 and 180 days after bev, whichever is longer.&#xD;
&#xD;
               -  Inclusion Criteria for Cohort A:&#xD;
&#xD;
          -  Disease progression following not more than one prior line of treatment for mCRC that&#xD;
             consisted of oxaliplatin or irinotecan containing chemotherapy in combination with a&#xD;
             biologic agent&#xD;
&#xD;
               -  Inclusion Criteria for Cohort B:&#xD;
&#xD;
          -  Disease progression during or following not more that two separate lines of treatment&#xD;
             for mCRC that consisted of oxaliplatin, and irinotecan containing chemotherapy in&#xD;
             combination with a biologic agent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous anticancer treatment within 4 weeks prior to initiation of study treatment&#xD;
&#xD;
          -  Prior allogeneic stem cell or solid organ transplant&#xD;
&#xD;
          -  Treatment with systemic immunostimulatory agents within 4 weeks prior to initiation of&#xD;
             study treatment&#xD;
&#xD;
          -  Use of any live vaccines against infectious diseases within 28 days of first dose.&#xD;
&#xD;
          -  Symptomatic, untreated, or actively progressing central nervous system (CNS)&#xD;
             metastases&#xD;
&#xD;
          -  Current treatment with anti-viral therapy for HBV&#xD;
&#xD;
          -  Structurally unstable bone lesions suggesting impending fracture&#xD;
&#xD;
          -  History or leptomeningeal disease&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced&#xD;
             pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening&#xD;
             chest CT scan&#xD;
&#xD;
          -  History of malignancy other than colorectal cancer within 2 years prior to screening,&#xD;
             except for malignancies such as non-melanoma skin carcinoma or ductal carcinoma in&#xD;
             situ&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Treatment with therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior&#xD;
             to initiating study treatment&#xD;
&#xD;
          -  Severe infection within 4 weeks (28 days) prior to initiation of study treatment&#xD;
&#xD;
          -  Significant cardiovascular disease, unstable or new onset of angina within 3 months&#xD;
             prior to initiation of treatment, or myocardial infarction within 6 months prior to&#xD;
             study treatment or unstable arrhythmia&#xD;
&#xD;
          -  Major surgical procedures, other than for diagnosis, within 4 weeks prior to&#xD;
             initiation of study treatment, or anticipation of need for major surgical procedure&#xD;
             during the study&#xD;
&#xD;
          -  Known allergy or hypersensitivity to any of the study drugs or their excipients&#xD;
&#xD;
          -  Inability to swallow medications&#xD;
&#xD;
          -  Malabsorption condition that would alter the absorption of orally administered&#xD;
             medications&#xD;
&#xD;
          -  Evidence of inherited bleeding diathesis or significant coagulopathy at risk of&#xD;
             bleeding (i.e., in the absence of therapeutic anticoagulation)&#xD;
&#xD;
          -  Prior treatment with an agent targeting the adenosine pathway&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiency, including, but not&#xD;
             limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid&#xD;
             antibody syndrome, Wegener granulomatosis, SjÃ¶gren syndrome, Guillain BarrÃ© syndrome,&#xD;
             or multiple sclerosis&#xD;
&#xD;
               -  Exclusion Criteria for Cohorts A and B:&#xD;
&#xD;
          -  Prior treatment with immune checkpoint blockade therapies including anit-cytotoxic T&#xD;
             lymphocyte-associated protein-4, anti PD-1, and anti-PD-L1 therapeutic antibodies&#xD;
&#xD;
          -  Mutation in the BRAF oncogene. Patients with unknown BRAF status will be required to&#xD;
             undergo testing at a local laboratory and provide results at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Director</last_name>
    <phone>(510)694-6200</phone>
    <email>clinicaltrials@arcusbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Olumide Gbolahan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tanios Bekaii-Saab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Clinical Research Center, Inc</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haley King</last_name>
    </contact>
    <contact_backup>
      <last_name>Nicole Sisk</last_name>
      <email>nsisk@acrcresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Manuel R Modiano-Revah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mengsha Li</last_name>
      <email>meli@coh.org</email>
    </contact>
    <investigator>
      <last_name>Marwan Fakih</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Zev Wainberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Wiess</last_name>
      <email>christina.wiess@yale.edu</email>
    </contact>
    <investigator>
      <last_name>MIchael Cecchini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sibley Memorial Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016-2633</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Wood</last_name>
      <email>bwood25@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Pishvaian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute at Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathleen F Coleman</last_name>
      <email>kathleen.marie.coleman@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>KJ Lee</last_name>
      <email>kyungjong.lee@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bassel El-Rayes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center (OMC)</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jonathan Mizrahi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Oncology Partners of Maryland,PA</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Rosello</last_name>
      <email>eileen.rosello@aoncology.com</email>
    </contact>
    <investigator>
      <last_name>Mark Goldstein,</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Katrina Pedersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers Of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna S Schmit</last_name>
      <email>johanna.schmit@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Fadi Braiteh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center - NYU Medical Oncology Associates</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Oberstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York-Presbyterian Hospital-Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rachael Safyan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania - Perelman Center for Advanced Medicine - Penn Radiation Oncology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mark O'Hara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health-Upstate</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ki-Young Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Johanna Bendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cathy Eng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Edmund Kopetz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin School of Medicine</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dustin Deming, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Hotel Dieu</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitie-Salpetriere-Centre De Recherche et de Medecine de l'Obesite</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU la Miletrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Anne</name>
      <address>
        <city>Strasbourg</city>
        <zip>67085</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen Medizinische Klinik III</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charite - Universitatsmedizin Berlin - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest GmbH - Institut Fuer Klinisch-Onkologische Forschung (IKF)</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaeres Krebszentrum Leipzig (UCCL)-Universitatsklinikum Leipzig AoR</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsmedizin Mannheim GmbH</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Grosshadern-Klinikum Der Ludwig-Maximilian Universitaet Muenchen</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Muenchen Bogenhausen</name>
      <address>
        <city>Muenchen</city>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ircc Istituto Per La Ricerca E La Cura Del Cancro Di Candiolo Oncologia Medica</name>
      <address>
        <city>Candiolo</city>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS - Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis</name>
      <address>
        <city>Castellana Grotte</city>
        <zip>70013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi-S.O.D. Patologia Medica</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Niguarda Ca' Granda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas IRCCS</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universita di Siena - Azienda Ospedaliera Universitaria Senese-Policlincio Santa Maria Alle Scotte</name>
      <address>
        <city>Siena,</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital (SNUH)</name>
      <address>
        <city>Seoul</city>
        <zip>3080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center, University of Ulsan College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>5538</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>8241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site #1</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site #2</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site #3</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Orense</name>
      <address>
        <city>Orense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad Navarra-Sede Madrid</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques De Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mCRC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Arcus will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

